Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

Hair loss treatments, including finasteride and RU58841, with humorous speculation about the cause of death for an ancient mummy that still had hair.

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

Topical finasteride as a potential alternative to oral finasteride for reducing DHT levels on the scalp with fewer side effects, and other hair loss treatments such as minoxidil.

The conversation humorously acknowledges the role of mice in testing Minoxidil for hair loss while also discussing the ethics of animal testing. Some users argue against animal testing, citing cruelty, while others defend its necessity for medical advancements.

The conversation discusses hair loss, genetics, and treatments like Dutasteride. It highlights the influence of genetics on hair loss, noting that indigenous people are less prone to it.

The conversation discusses skepticism and mixed opinions about a hair loss theory, mentioning treatments like Minoxidil, finasteride, RU58841, and Procyanidin B2. There is criticism of a content creator named HairCafe and the difficulty in obtaining effective sulforaphane supplements.

Experimenting with the effects of creatine and finasteride on DHT levels, as well as a discussion regarding the potential link between creatine supplementation and hair loss.

Poor diet and lifestyle contribute to male pattern baldness. Treatments like Minoxidil, dietary changes, and lifestyle adjustments may help slow hair loss.

Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The user is experiencing progressive hair thinning despite using finasteride and dutasteride. A biopsy confirmed male pattern baldness, and minoxidil was suggested as an additional treatment.

A woman who has been experiencing hair loss for several years, and her question of whether there is any benefit to getting a biopsy to check if it's AGA or diffuse alopecia areata when no cure or very effective treatment exists. Treatments such as spironolactone and Minoxidil/finasteride/RU58841 have previously been discussed.

The original poster believes shaving his head made him more attractive to a specific group of women, despite being less attractive overall. The conversation includes various opinions on attractiveness, with some agreeing that being bald can work for certain men, while others suggest maintaining hair is generally more appealing.

A user discusses their habit of analyzing others' hair due to their own hair thinning at 18. Another user mentions starting finasteride in 2010 and still having a full head of hair.

Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.

The user experienced male pattern baldness starting at 18, tried finasteride with no success, and switched to dutasteride, which halted hair loss. Minoxidil had no effect for them, while their brother, who didn't use AR inhibitors, maintained a juvenile hairline and successfully grew a beard with minoxidil, highlighting the unpredictable nature of genetics in hair loss and treatment response.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The conversation discusses hair loss treatments, specifically finasteride, minoxidil, ketoconazole shampoo, and microneedling, with users experiencing initial success followed by increased shedding and regression. Many users suggest patience, as hair cycles can take years, and some attribute changes to seasonal shedding.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

A user is frustrated about early balding despite older male relatives retaining hair into old age. Another user plans to start finasteride soon to address their hair thinning.

The user is concerned about high DHT levels despite using finasteride and dutasteride for hair loss, suggesting these treatments may not be effective. They plan to consult an endocrinologist and consider other antiandrogens, acknowledging potential side effects.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

Some individuals experience side effects from 5AR inhibitors like finasteride and are considering hair transplants without these medications, with some opting for surgeons like Dr. Zarev. Others are exploring alternative treatments and waiting for new medications in development, while some discuss managing side effects through lifestyle changes or additional medications.

The conversation discusses potential hair loss treatments, including methylating estrogen, losing body fat, and supplementing with vitamins A, K2, and D. It also mentions reducing exposure to environmental estrogenics, with skepticism about genetic factors being the primary cause of baldness.

Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.

A 21-year-old male suffering from male pattern baldness is using topical finasteride and minoxidil, and oral minoxidil. His bloodwork shows normal DHT levels and slightly high testosterone, leading to discussions about the role of DHT sensitivity in hair loss, the potential impact of finasteride on his DHT levels, and the suggestion to proceed with oral finasteride due to his high testosterone.